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Willingness to Pay in Dermatology: Assessment of the
Burden of Skin Diseases
Anne M. Seidler1, Ahmed M. Bayoumi2,3,4, Mary K. Goldstein5,6,7, Ponciano D. Cruz Jr8 and
Suephy C. Chen1,9
Willingness to pay (WTP) is a monetary, preference-based, burden-of-disease measure with a potential role in
dermatology, where many conditions are temporary and/or mild, and many treatments are inexpensive and one
might be able to imagine paying out of pocket. We assessed construct validity by interviewing 254 consecutive
dermatology patients at Stanford Medical Center, Grady Hospital, and Parkland Hospital. Instruments asked
about an individual’s own health status and elicited WTP, time-trade-off (TTO) utilities, and health status quality
of life (QOL). We measured WTP cure (short treatment course to eliminate disease) and WTP control (lifelong
medication). Our data indicate greater construct validity in non-Medicaid (n¼ 163) than Medicaid (n¼ 91)
patients. Non-Medicaid subjects had greater WTP as percent of income for cure (median: 2%) than control
(median: 1.6%), Po0.01; Medicaid WTP amounts for control and cure did not differ. Non-Medicaid subjects with
verrucae had little QOL impact, no measurable burden by TTO, and a correspondingly low WTP. Medicaid
subjects with basal cell carcinoma had a strong, negative QOL impact and high burden by TTO, but had
relatively moderate WTP. WTP appears promising in certain income categories. More studies are needed for
conclusions about specific diagnoses.
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INTRODUCTION
A goal of the dermatology community is to quantify the
burden of skin disease by measures of prevalence, quality of
life (QOL), and costs of illness (Chen et al., 2004). There are
various measures for assessing QOL impact, including
descriptive and detailed health status instruments, such as
the Skindex (Chren et al., 1997); utilities derived from
techniques such as standard gamble or time-trade-off (TTO)
methods; and the willingness-to-pay (WTP) metric. Health
status instruments are actively explored in the literature and
data regarding utilities are emerging, but exploration of WTP
in dermatology is in its infancy.
WTP is a measure of disease burden that may be acquired
by directly asking patients what amounts they would be
willing to pay to rid themselves of their own specific health
condition. WTP is distinct from a utility, which is also a
measure of disease burden, because WTP is based on
contingent valuation whereby units are expressed in monetary
terms. Contingent valuation aims to provide a market value to
nonmarket goods, such as health status. The WTP method is
theoretically advantageous over utilities in so-called minor
health states, because asking patients to consider paying
relatively small amounts of money may be more intuitive than
asking them to contemplate trading time from their life
expectancy (as in one method of calculating utilities).
Our purpose is to introduce WTP across a variety of skin
diseases to the dermatology community. We prospectively
gathered WTP data directly from subjects with a variety of
skin diseases to collect a repository of WTP amounts. We
then performed post hoc subjective analyses to assess
construct validity, defined as the ability of WTP to measure
the disease burden it purports to measure. We assessed
whether WTP responses seemed meaningful, based on QOL
impact (as measured by the Skindex questionnaire) and TTO
utility responses. We assumed that individuals with little
discretionary income, in subsidized programs, would not be
as accustomed to payment decisions that WTP aims to
capture. Accordingly, we separated subjects eligible for
Medicaid based on their income from the rest of the sample
with greater income levels for the analyses.
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RESULTS
Sample
We recruited a total of 283 subjects: 77 from Grady Hospital,
106 from Stanford Medical Center, and 100 from Parkland
Hospital. The proportion of subjects approached who agreed
to be interviewed by site was 97% at Grady, 25% at Stanford,
and 67% at Parkland. A language barrier was the most
common reason for declining at Parkland. Patients at Grady
(a safety-net institution serving low-income patients) were
willing to donate 20–30minutes of their time for an interview,
whereas at Stanford the patients were much less willing to
spend their time participating in an interview. We eliminated
eight participants from Grady who did not complete the TTO
questions and four additional subjects (three from Stanford
and one from Grady) who gave inconsistent responses to the
utility questions. For example, some subjects indicated that
their health utility for all illnesses was greater than their skin-
only utility. We eliminated six additional subjects from
Stanford who were willing to pay a one-time amount for cure
exceeding their total annual income. Finally, we eliminated 11
subjects with multiple skin diagnoses (three from Grady, seven
from Stanford, and one from Parkland) because our goal was to
distinguish WTP amounts by individual diagnoses. Accord-
ingly, our final analyses were based on data from 254 subjects
(65 from Grady, 90 from Stanford, and 99 from Parkland).
Demographics and descriptives
Demographic and descriptive information is displayed in
Table 1 according to income because WTP values may vary
by ability to pay (Bala et al., 1999a). The methods section
provides an explanation of the meaning of symptom/emotion/
function scores. The majority of our patient sample (64%) had
Table 1. Demographics and descriptives for entire patient sample and by income group
All income groups Income p$10,070 Income 4$10,070
N (% sample) 254 (100%) 91 (36%) 163 (64%)
Demographics
Age: median (IQR) 45 (35, 58) 45 (35, 59) 44 (33, 58)
Income: median (IQR) $15,000 ($7,500, $50,000) $7,500 ($5,000, $7,500) $35,000 ($15,000, $85,000)
Gender: N (% sample)
1: Male 1: 113 (44) 1: 33 (36) 1: 80 (49)1
Race: N (% sample)
1: Non-white 1: 125 (49) 1: 61 (67) 1: 64 (39)2
Education (highest level completed): N (% sample)
1: Grade school 1: 13 (5) 1: 8 (9) 1: 5 (3)3
2: High school 2: 109 (43) 2: 64 (70) 2: 45 (28)
3: College 3: 73 (29) 3: 14 (15) 3: 59 (36)
4: Graduate school 4: 53 (21) 4: 2 (2) 4: 51 (31)
5: Unknown 5: 6 (2) 5: 3 (3) 5: 3 (2)
Descriptives: median (IQR)
WTP cure
1: One-time amount 1: $300 ($100, $2,000) 1: $100 ($50, $200) 1: $1,000 ($200, $5,000)2
2: Percent of annual income 2: 1.63 (0.67, 6.10) 2: 1.33 (0.67, 4.00) 2: 2.00 (0.67, 8.00)
WTP control
1: Monthly amount 1: $30 ($16, $100) 1: $20 ($10, $30) 1: $50 ($25, $100)2
2: Percent of annual income 2: 2.40 (0.72, 4.80) 2: 4.80 (2.40, 7.20) 2: 1.60 (0.48, 4.00)2
Utility 1.00 (0.94, 1.00) 1.00 (0.86, 1.00) 1.00 (0.97, 1.00)1
Symptom 0.68 (0.50, 0.86) 0.61 (0.46, 0.82) 0.71 (0.54, 0.89)2
Emotion 0.72 (0.50, 0.85) 0.69 (0.47, 0.81) 0.72 (0.50, 0.85)
Function 0.92 (0.73, 1.00) 0.88 (0.73, 1.00) 0.92 (0.73, 1.00)
Abbreviation: IQR, interquartile range.
1Po0.05 by Mann–Whitney U-test.
2Po0.01 by Mann–Whitney U-test.
3Po0.01 by Pearson w2-test for independence of proportions.
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an annual household income exceeding $10,070, and thus
was not eligible for Medicaid. We will refer to this group as
the non-Medicaid group. We will refer to patients with
annual household incomes of p$10,070 as the Medicaid
group, as these patients were eligible for the Medicaid
program at the time of data acquisition.
The non-Medicaid group consisted of a greater proportion
of subjects who were male and white than the Medicaid
group (Po0.05); there was no significant difference by age.
The Medicaid group had more subjects who did not attend
college (Po0.01). The non-Medicaid group had greater
absolute values of WTP control and WTP cure but had
greater TTO utility (Po0.05), indicating less burden of
disease. Utility, symptom, emotion, and function by income
group are presented in Figure 1a–d. The non-Medicaid group
had less symptomatic impact (Po0.01). When WTP control
and cure were calculated as proportions of annual income,
the Medicaid group had a greater WTP control than the non-
Medicaid group (median: 4.80 vs. 1.60, Po0.0001), but there
was no significant difference between the Medicaid and non-
Medicaid groups in WTP cure (median: 1.33 vs. 2.00,
P¼0.369). There were only four subjects with WTP values
of $0 for cure (three non-Medicaid and one Medicaid).
Twelve subjects had WTP values of $0 for control (seven non-
Medicaid and five Medicaid).
Diagnosis
Our patient sample was representative of over 80 diagnoses,
but we report descriptive data for 8 diagnoses that included at
least 5 patients. These diagnoses are represented in Table 2a
and b, by income category (4$10,070 or p$10,070), and
together they account for 34% of our sample. Specific
diagnoses with fewer than five patients included varicosities,
vitiligo, rosacea, pemphigus vulgaris, sarcoidosis, melasma,
lichen planus, dyshidrosis, and alopecia among many others.
WTP construct validity
On the individual level, WTP control was never reported
greater than WTP cure in either income group. Eleven subjects
had equal WTP cure and WTP control amounts. It is
noteworthy that when all income groups and all diseases were
considered (n¼254) there was no significant difference
between WTP cure (median: 1.63%) and WTP control (median:
2.40%) amounts as percentages of annual income (P¼0.877).
Non-Medicaid sample
Patients with verrucae had the least QOL impact as reflected
by relatively high Skindex scores (Table 2a). They also had a
median utility of 1, indicating little, if any, preference for
another state. Correspondingly, this group of patients had the
lowest relative WTP cure amounts as a percentage of annual
income. On the other extreme, patients with psoriasis had the
most QOL impact by Skindex measures and the greatest
burden of disease by TTO utility. Psoriasis patients had the
highest WTP control amounts; the WTP cure was relatively
large as well, second only to the WTP cure amount for actinic
keratosis. The actinic keratosis group had a relatively high
WTP cure, but this group was relatively unwilling to pay a
large amount for control of these premalignant lesions.
Medicaid sample
Patients with basal cell carcinoma had the least QOL impact
by Skindex scores (Table 2b). However, the utility value was
relatively low, indicating greater preference for another state,
and the WTP control and cure amounts as percentages of
income were relatively moderate. Patients with acne had the
greatest QOL impact by Skindex. However, the TTO utility
value was 1, indicating little to no preference for another
state, and the WTP cure amount was low.
DISCUSSION
WTP appears to be a promising measure of the burden of skin
disease. We found that all subjects responded that their WTP
cure was greater than WTP control, as anticipated, except
the 11 subjects who gave equal values for control and cure.
Our preliminary data indicate that WTP may have greater
construct validity for non-Medicaid patients than Medicaid
patients. Our post hoc assessment of the meaningfulness of
WTP responses, given the corresponding QOL impact and
TTO utilities, revealed that WTP responses from the non-
Medicaid group were consistent with our expectations of
these amounts, whereas responses from the Medicaid group
were inconsistent.
We anticipated that patients with the greatest QOL impact
from their skin disease would be willing to pay the most
to either control or cure their disease, and we witnessed
the expected responses in non-Medicaid subjects. The WTP
responses from the Medicaid group differed from the
anticipated amounts from corresponding TTO utility and
QOL measures. For example, psoriasis subjects had greater
emotional and functional impact than eczema patients, but
were willing to pay relatively less for a cure.
Our study has relevant limitations. The small number of
subjects when divided by diagnosis limited our analyses.
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Figure 1. QOL Skindex measures by income group. (a–d) Utility, symptom,
emotion, and function by income group.
www.jidonline.org 1787
AM Seidler et al.
Assessment of the Burden of Skin Diseases
There may be other factors that influenced the WTP
responses, such as age, gender, or duration of disease, which
we did not explore in this study. Further, these factors could
have differed between the Medicaid and non-Medicaid
subjects with a given disease, and could account for the
differences in responses we saw in these groups. Future
studies should evaluate the influence of these other variables
on WTP responses. Second, our patient sample may have
been subject to selection bias, as it comprised individuals
who agreed to an interview lasting 20–30minutes, and their
personal characteristics may have differed from the popula-
tion as a whole or they may have had more significant disease
burden than those who were not willing to donate time for an
interview.
We calculated correlation coefficients for WTP and utilities
that were low as expected; however, we do not present these
data here, as it contributes little to the evaluation of whether
WTP is a meaningful measure of disease burden for many
reasons. WTP and utilities are different currencies. As a
contingent valuation measure expressed in monetary terms,
WTP is different, by nature, from utility measures. People feel
differently about money they would be willing to pay and
time they would be willing to trade from their lives for an
improved health status. For instance, some individuals may be
willing to pay large sums of money, but would not be
interested in trading any time from their lives, because of their
perspective on these very different entities. Similarly, another
individual may be willing to trade in time from life before
spending large sums of money.
Prior work has demonstrated modest correlation, at best,
between preference-based measures, including utilities and
WTP and health status instruments such as Skindex symptom,
emotion, and functional status (Goldstein and Tsevat, 2003).
Bala et al. (1998) demonstrated that Quality-adjusted life
years (a measure that incorporates utilities and life years) and
WTP are weakly correlated, supporting the fact that they may
measure different aspects of patient preference. Lundberg
et al. (1999) examined utilities and WTP in patients with
psoriasis and atopic dermatitis. The authors found a weak
correlation (r¼0.133, Po0.05) between TTO utilities and
WTP as assessed by the dichotomous choice method.
Other authors have helped elucidate components of patient
preference that may account for weak correlations between
WTP and utilities. Bala et al. (1999b) demonstrated the
importance of the duration of an illness. The authors compared
utilities associated with 10 vs. 20 years of shingles pain and
demonstrated that a smaller amount of time with the condition
yielded less burden of disease (Bala et al., 1999b). Franic et al.
(2005) examined acute (post-chemotherapy nausea and
vomiting) versus chronic (breast cancer) conditions. The
authors found limitations in the use of utilities in acute
conditions and in the use of WTP in chronic conditions.
Enduring a time-limited illness may be preferable to trading
time from one’s life expectancy. In terms of a chronic
condition, the burden may be so extensive that it cannot be
effectively captured in monetary terms, particularly because of
a lack of experience in funding or even conceptualizing the
costs of extensive treatments over time. Accordingly, WTP
may be more appropriate for measuring health benefits for
acute conditions (Bala and Zarkin, 2000), whereas utilities
may be more applicable for assessing burden in chronic
conditions.
The interest in WTP as a preference-based measure to
inform decision-makers or for other population-based ana-
lyses may be characterized as follows. (1) WTP is a measure
of QOL that may be incorporated into pharmacoeconomic
analyses, such as cost–benefit analyses; (2) WTP can capture
aspects of health that patients may consider important, but
are not necessarily captured with conventional effectiveness
measures (Thompson, 1986; Drummond and Jefferson, 1996;
Table 2. (a) Non-Medicaid patients and (b) Medicaid patients
WTP as % of income median (IQR) Skindex median (IQR)
Income 4$10,070 TTO median (IQR) Control Cure Symptom Emotion Function
(a)
Acne (n=24) 1.00 (0.98, 1.00) 2.00 (0.59, 4.27) 1.63 (0.67, 6.32) 0.75 (0.65, 0.85) 0.62 (0.46, 0.75) 0.92 (0.76, 1.00)
Psoriasis (n=8) 0.95 (0.67, 1.00) 3.20 (1.71, 8.26) 9.88 (1.83, 58.57) 0.41 (0.19, 0.64) 0.44 (0.06, 0.78) 0.54 (0.30, 0.93)
Actinic keratosis (n=7) 1.00 (0.83, 1.00) 0.60 (0.21, 2.67) 11.11 (5.71, 24.00) 0.82 (0.57, 1.00) 0.75 (0.68, 0.95) 1.00 (0.88, 1.00)
Epidermoid cyst (n=5) 0.99 (0.96, 1.00) 0.96 (0.48, 6.80) 2.00 (0.60, 5.33) 0.86 (0.79, 0.93) 0.72 (0.66, 0.89) 1.00 (0.74, 1.00)
Verrucae (n=6) 1.00 (0.96, 1.00) 0.92 (0.24, 4.00) 0.89 (0.46, 1.47) 0.93 (0.74, 1.00) 0.96 (0.81, 1.00) 1.00 (0.91, 1.00)
(b)
Acne (n=6) 1.00 (0.88, 1.00) 3.60 (1.20, 24.00) 1.07 (0.20, 6.00) 0.46 (0.35, 0.63) 0.54 (0.09, 0.74) 0.73 (0.67, 0.89)
Psoriasis (n=15) 0.93 (0.75, 1.00) 3.20 (0.80, 7.20) 1.33 (0.67, 4.00) 0.46 (0.39, 0.64) 0.58 (0.47, 0.81) 0.75 (0.71, 0.92)
Eczema (n=6) 1.00 (0.98, 1.00) 3.60 (1.80, 26.70) 2.33 (0.47, 13.50) 0.43 (0.32, 0.65) 0.69 (0.40, 0.92) 0.92 (0.85, 0.97)
Contact dermatitis (n=5) 0.98 (0.67, 1.00) 7.20 (4.80, 20.00) 2.67 (0.97, 76.67) 0.54 (0.30, 0.66) 0.72 (0.50, 0.81) 0.83 (0.74, 0.84)
Basal cell carcinoma (n=5) 0.95 (0.88, 1.00) 4.80 (1.40, 8.40) 1.33 (0.97, 16.33) 0.57 (0.45, 0.77) 0.72 (0.61, 0.93) 0.94 (0.81, 1.00)
Abbreviations: IQR, interquartile range; TTO, time trade off; WTP, willingness to pay.
Burden of skin disease by specific diagnosis (groups included had nX5 patients).
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Olsen and Smith, 2001). For example, WTP may capture a
desire for personal attention or other intangible components
of the process of care (Drummond and Jefferson, 1996). (3)
WTP may account for other aspects of a disease that are
difficult to measure, such as disfigurement or fear. (4) As a
monetary measure, WTP may be added to conventional
calculations of direct costs and loss of productivity included
in cost of illness studies (Thompson, 1986). It has been argued
that without the inclusion of WTP measures, cost of illness
calculations are underestimates of the true economic burden
of disease (Landefeld and Seskin, 1982; Goddeeris, 1983).
In summary, our data support the fact that practical
applications of the WTP method are likely limited to
individuals with incomes above the Medicaid-eligible level.
A thorough assessment of the relevance of WTP to specific
dermatologic diseases is beyond the scope of this work.
Although some dermatologic diseases can be costly or
chronic, a significant number of them represent acute or
relatively inexpensive conditions that may lend themselves to
WTP. Our data indicate that WTP is promising in non-
Medicaid patients, given that the responses are subjectively
meaningful in the context of other corresponding burden of
disease and health status measures in this group. Thus, further
work into WTP in dermatology is warranted.
MATERIALS AND METHODS
Subjects and data collection
We refer the reader to the materials and methods section of our
previous paper (Chen et al., 2004), as the data for the current study
were derived from the same patient population. Briefly, subjects were
recruited consecutively from general dermatology clinics at Stanford
Medical Center (Stanford, CA), Grady Hospital (Atlanta, GA), and
Parkland Hospital (Dallas, TX). Institutional Review Board approval
was obtained from each institution, and informed consent was
obtained from each subject. The investigation was conducted
according to the Declaration of Helsinki principles. One interviewer
at each site administered all questionnaires, and all interviewers were
trained by the author, SCC. Both patients and dermatologists were
asked about the specific diagnosis that led to the visit. In cases where
the responses conflicted, the response of the dermatologist was used.
Prospective stratification of sample by Medicaid status
We prospectively stratified the analyses according to Medicaid status
for the following reasons. We hypothesized that people on subsidized
programs may not be accustomed to paying out of their own funds,
and accordingly they may answer the questions about WTP differently
from people not on subsidized programs. In addition, we considered
that people with little discretionary income might not be willing or
able to pay larger amounts of money to improve their health status.
Skin disease severity measurement
Medical records were obtained for all study subjects from Grady
Hospital and Stanford Medical Center in order to retrospectively
classify skin disease severity on a three-point scale (mild, moderate,
and severe). Three practicing dermatologists reviewed the records at
the time of the original survey administration. Parkland Hospital
charts were unavailable for review for the original cohort, and thus
an additional cohort of subjects was recruited from that site. Thus,
the patient sample from Parkland Hospital for the current study
differs from that of our previous study (Chen et al., 2004).
Willingness-to-pay elicitation
Subjects were asked about the amount of money they would be
willing to pay out of pocket for two hypothetical drugs, one for
control (WTP control) and the other for cure (WTP cure) of their skin
disease. An open-ended question format was used. For the WTP
control question, patients were asked how much they would pay on
a monthly basis to control the clinical signs of their skin condition.
Patients were instructed that insurance would not cover the costs of
the medication, and if they stopped taking their medication their skin
condition would recur immediately. The monthly cost of the
hypothetical medication was then recorded. The WTP control
monthly amount was converted to an annual sum for all patients.
The annual WTP control values were divided by the patient’s self-
reported household income from the past year, for assessment as a
percentage of annual income. For the WTP cure question, patients
were asked how much they would pay as a one-time cost for an
imaginary cure for their skin condition. They were instructed that the
hypothetical cure was not covered by insurance and that it had no
side effects. WTP cure was also calculated as percentage of annual
income. A higher WTP value indicated a higher disease burden.
In Spearman’s correlation calculations and the regression
analysis, WTP as an absolute value was used.
Skindex questionnaire
The Skindex-29 (Chren et al., 1997) is a previously validated skin-
specific health status measure that may be applied to all skin
conditions. The questions are grouped into three constructs:
symptoms (e.g., pain, pruritus, bleeding, and so on), functional
impact (e.g., closeness with loved ones, tendency to stay at home,
and so on), and emotional impact (e.g., humiliation, embarrassment,
shame, and so on). Each question in the Skindex-29 questionnaire
has five answer choices, indicating the level of impact, with 1 as the
least and 5 as the most. We converted the Skindex scores to a range
from 0 (greatest amount of impact) to 1 (no impact).
Utility elicitation
A detailed description of the utility elicitation is included in our
previous study (Chen et al., 2004).
Statistical analysis
Analyses were performed using the Statistical Analysis System
software and SPSS version 16.0 for Windows. Medians and
interquartile ranges were used for continuous variables describing
characteristics of the sample because the distributions were
nonparametric. Mann–Whitney U-tests were used to compare
medians of unrelated samples. Wilcoxon’s signed ranks test was
used to compare paired data (e.g., WTP control and WTP cure).
Proportions were used to describe categorical variables and w2-tests
were used to compare group differences. Spearman’s correlation
coefficients were calculated owing to the nonparametric nature of
the data, and P-values were calculated as two-tailed tests. All
P-values o0.05 were considered statistically significant.
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